The role of systemic therapy in borderline resectable and locally advanced pancreatic ductal adenocarcinoma

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a deadly disease, even in patients whose cancer is localized and non-metastatic. Surgical resection provides the only option for cure, but long-term survival rates remain dismal. For patients with borderline resectable (BR) disease who undergo upfront resection, many patients are either too unwell for subsequent adjuvant systemic therapy, develop recurrence soon after, or are found to have unresectable disease intra-operatively. There is increasing evidence for a neoadjuvant approach, using more conventional multi-agent chemotherapy regimens, which have demonstrated higher activity in the metastatic setting compared to single agents. For patients with locally advanced (LA) disease, which is unresectable by current definitions, there is mounting evidence that effective neoadjuvant systemic therapy is able to convert some patients’ disease to a resectable state, offering the potential for long-term survival and cure. Herein we present a review of key trials focusing on prospective, randomized studies to provide high-level evidence supporting a neoadjuvant approach to both BR and LA PDAC. However, many knowledge gaps exist, such as the optimal neoadjuvant multi-agent chemotherapy regimen, the role of radiotherapy, and the safety and efficacy of adding immunotherapy to chemo/radiation therapy. Future challenges in determining the optimal approach to patients with BR or LA PDAC include not only overcoming the inherent difficulties in conducting complex, multidisciplinary, multicentre randomized trials in patients with a high-morbidity and mortality disease, but also trying to standardize disease definitions, treatment regimens, and outcome measures.

Keywords

Borderline resectable / locally advanced / pancreatic ductal adenocarcinoma / neoadjuvant chemotherapy

References

[1] Lippi G.The global burden of pancreatic cancer.Arch Med Sci2020;16:820-4 PMCID:PMC7286317

[2] Lee S. Canadian cancer statistics 2021. Available from: https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics [Last accessed on 5 August 2022].

[3] Siegel RL,Fuchs HE.Cancer statistics, 2022.CA Cancer J Clin2022;72:7-33

[4] Katanoda K,Saito E.Updated trends in cancer in japan: incidence in 1985-2015 and mortality in 1958-2018-a sign of decrease in cancer incidence.J Epidemiol2021;31:426-50 PMCID:PMC8187612

[5] Ferlay J,Soerjomataram I.Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018.Eur J Cancer2018;103:356-87

[6] Paniccia A,Henderson W.Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma.JAMA Surg2015;150:701-10

[7] Stathis A.Advanced pancreatic carcinoma: current treatment and future challenges.Nat Rev Clin Oncol2010;7:163-72

[8] Conroy T,Hebbar M.FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer.N Engl J Med2018;379:2395-406

[9] Neoptolemos JP,Ghaneh P.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.Lancet2017;389:1011-24

[10] Tempero MA,Riess H.APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.JCO2019;37:4000

[11] Versteijne E,Besselink MG.Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.Br J Surg2018;105:946-58 PMCID:PMC6033157

[12] Klinkenbijl JH,Sahmoud T.Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.Ann Surg1999;230:776-82; discussion 782 PMCID:PMC1420941

[13] Versteijne E,Suker M.Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the dutch randomized preopanc trial.J Clin Oncol2022;40:1220-30

[14] Jang JY,Lee H.Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial.Ann Surg2018;268:215-22

[15] Murphy JE,Ryan DP.Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial.JAMA Oncol2018;4:963-9 PMCID:PMC6145728

[16] Ghaneh P,Cicconi S.ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer.JCO2020;38:4505-4505

[17] Reni M,Balzano G.A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.Eur J Cancer2018;102:95-102

[18] Hammel P,van Laethem JL.Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial.JAMA2016;315:1844-53

[19] Murphy JE,Ryan DP.Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial.JAMA Oncol2019;5:1020-7 PMCID:PMC6547247

[20] Philip PA,Portales F.Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.Lancet Gastroenterol Hepatol2020;5:285-94

[21] Kunzmann V,Algül H.Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.Lancet Gastroenterol Hepatol2021;6:128-38

[22] Pancreatic Adenocarcinoma NCCN Guidelines Version 1.2022. NCCN. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455 [Last accessed on 5 August 2022].

[23] Vauthey JN.AHPBA/SSO/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference.Ann Surg Oncol2009;16:1725-6

[24] Varadhachary GR. Borderline resectable pancreatic cancer, Pancreatic Cancer. New York: Springer; 2018. pp. 1001-20. Available from: http://www.scopus.com/inward/record.url?scp=85054047248&partnerID=8YFLogxK [Last accessed on 5 August 2022].

[25] Katz MH,Herman JM.Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design.Ann Surg Oncol2013;20:2787-95 PMCID:PMC5600517

[26] Isaji S,Windsor JA.International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017.Pancreatology2018;18:2-11

[27] Bockhorn M,Adham M.Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS).Surgery2014;155:977-88

[28] Von Hoff DD,Arena FP.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;369:1691-703 PMCID:PMC4631139

[29] Conroy T,Ychou M.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;364:1817-25

[30] Janssen QP,Suker M.Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis.J Natl Cancer Inst2019;111:782-94 PMCID:PMC6695305

[31] Versteijne E,Groothuis K.Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial.J Clin Oncol2020;38:1763-73 PMCID:PMC8265386

[32] Katz MHG,Herman JM.Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.BMC Cancer2017;17:505 PMCID:PMC5530569

[33] Katz MHG,Meyers JP.Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas.JCO2021;39:377-377

[34] Institut de Cancérologie de Lorraine. Two arm, prospective, multicenter randomized phase II trial of neoadjuvant modified folfirinox regimen, with or without preoperative concomitant chemoradiotherapy in patients with borderline resectable pancreatic carcinoma, 2022. Available from: https://clinicaltrials.gov/ct2/show/NCT02676349 [Last accessed on 5 August 2022].

[35] Suker M,Sadot E.FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.Lancet Oncol2016;17:801-10 PMCID:PMC5527756

[36] Wang S,Xing C.Tumor microenvironment in chemoresistance, metastasis and immunotherapy of pancreatic cancer.Am J Cancer Res2020;10:1937-53 PMCID:PMC7407356

[37] Palta M,Goodman KA.Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline.Pract Radiat Oncol2019;9:322-32